Trials / Recruiting
RecruitingNCT07054684
Study of BHV-1400 in IgA Nephropathy
An Open-Label Biomarker Study of BHV-1400 in IgA Nephropathy
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Biohaven Therapeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BHV-1400 | BHV-1400 is delivered subcutaneously (SC) |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2025-07-08
- Last updated
- 2026-03-10
Locations
12 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07054684. Inclusion in this directory is not an endorsement.